The absence of myelin basic protein promotes neuroinflammation and reduces amyloid β-protein accumulation in Tg-5xFAD mice

Journal of Neuroinflammation

Volumn 10, Issue , 2013, Pages

  Ou Yang, Ming Hsuan ^a   Van Nostrand, William E ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid protein; Astrocyte; Chaperone molecules; Matrix metalloproteinases; Microglia; Myelin basic protein; Transgenic mice

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; GELATINASE B; MYELIN BASIC PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CEREBROSPINAL FLUID; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PLASMA; PROTEIN EXPRESSION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MYELIN BASIC PROTEIN;

EID: 84887126975     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-10-134     Document Type: Article

References (79)

1. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741. 10.1126/science.286.5440.735, 10531052.
2. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998, 391:387-390. 10.1038/34910, 9450754.
3. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of γ-secretase activity. Nat Cell Biol 2003, 5:486-488. 10.1038/ncb960, 12679784.
4. Benilova I, Karran E, De Strooper B. The toxic aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012, 15:349-357. 10.1038/nn.3028, 22286176.
5. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 2007, 8:101-112. 10.1038/nrm2101, 17245412.
6. Selkoe DJ. Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior. Behav Brain Res 2008, 192:106-113. 10.1016/j.bbr.2008.02.016, 2601528, 18359102.
7. Urbanc B, Cruz L, Le R, Sanders J, Ashe KH, Duff K, Stanley HE, Irizarry MC, Hyman BT. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc Natl Acad Sci USA 2002, 99:13990-13995. 10.1073/pnas.222433299, 137824, 12374847.
8. McLellan ME, Kajdasz ST, Hyman BT, Bacskai BJ. In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J Neurosci 2003, 23:2212-2217.
9. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:1977-1981. 10.1073/pnas.90.5.1977, 46003, 8446617.
10. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem 1994, 269:23403-23406.
11. Holtzman DM. Role of apoE/Aβ interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. J Mol Neurosci 2001, 17:147-155. 10.1385/JMN:17:2:147, 11816788.
12. Matsubara E, Frangione B, Ghiso J. Characterization of apolipoprotein J-Alzheimer's Aβ interaction. J Biol Chem 1995, 270:7563-7567. 10.1074/jbc.270.13.7563, 7706304.
13. DeMattos RB, O'Dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, Paul SM, Aronow BJ, Holtzman DM. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2002, 99:10843-10848. 10.1073/pnas.162228299, 125060, 12145324.
14. Magrane J, Smith RC, Walsh K, Querfurth HW. Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed β-amyloid in neurons. J Neurosci 2004, 24:1700-1706. 10.1523/JNEUROSCI.4330-03.2004, 14973234.
15. Evans CG, Wisen S, Gestwicki JE. Heat shock proteins 70 and 90 inhibit early stages of amyloid β-(1-42) aggregation in vitro. J Biol Chem 2006, 281:33182-33191. 10.1074/jbc.M606192200, 16973602.
16. Yamamoto N, Hirabayashi Y, Amari M, Yamaguchi H, Romanov G, Van Nostrand WE, Yanagisawa K. Assembly of hereditary amyloid β-protein variants in the presence of favorable gangliosides. FEBS Lett 2005, 579:2185-2190. 10.1016/j.febslet.2005.03.013, 15811339.
17. Schwarzman AL, Goldgaber D. Interaction of transthyretin with amyloid β-protein: binding and inhibition of amyloid formation. Ciba Found Symp 1996, 199:146-160. discussion 160-144.
18. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of aβ toxicity. Proc Natl Acad Sci USA 2008, 105:2681-2686. 10.1073/pnas.0712197105, 2268196, 18272491.
19. van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM. Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol 2003, 2:482-492. 10.1016/S1474-4422(03)00484-8, 12878436.
20. Yanagisawa K, Odaka A, Suzuki N, Ihara Y. GM1 ganglioside-bound amyloid β-protein (Aβ): a possible form of preamyloid in Alzheimer's disease. Nat Med 1995, 1:1062-1066. 10.1038/nm1095-1062, 7489364.
21. Chi EY, Frey SL, Lee KY. Ganglioside G(M1)-mediated amyloid-beta fibrillogenesis and membrane disruption. Biochemistry 2007, 46:1913-1924. 10.1021/bi062177x, 17256880.
22. Hoos MD, Ahmed M, Smith SO, Van Nostrand WE. Inhibition of familial cerebral amyloid angiopathy mutant amyloid β-protein fibril assembly by myelin basic protein. J Biol Chem 2007, 282:9952-9961. 10.1074/jbc.M603494200, 17259179.
23. Boggs JM. Myelin basic protein: a multifunctional protein. Cell Mol Life Sci 2006, 63:1945-1961. 10.1007/s00018-006-6094-7, 16794783.
24. Campagnoni AT, Pribyl TM, Campagnoni CW, Kampf K, Amur-Umarjee S, Landry CF, Handley VW, Newman SL, Garbay B, Kitamura K. Structure and developmental regulation of Golli-mbp, a 105-kilobase gene that encompasses the myelin basic protein gene and is expressed in cells in the oligodendrocyte lineage in the brain. J Biol Chem 1993, 268:4930-4938.
25. Kamholz J, de Ferra F, Puckett C, Lazzarini R. Identification of three forms of human myelin basic protein by cDNA cloning. Proc Natl Acad Sci USA 1986, 83:4962-4966. 10.1073/pnas.83.13.4962, 323864, 2425357.
26. Roth HJ, Kronquist KE, Kerlero De Rosbo N, Crandall BF, Campagnoni AT. Evidence for the expression of four myelin basic protein variants in the developing human spinal cord through cDNA cloning. J Neurosci Res 1987, 17:321-328. 10.1002/jnr.490170402, 2442403.
27. Harauz G, Ishiyama N, Hill CM, Bates IR, Libich DS, Fares C. Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. Micron 2004, 35:503-542. 10.1016/j.micron.2004.04.005, 15219899.
28. de Ferra F, Engh H, Hudson L, Kamholz J, Puckett C, Molineaux S, Lazzarini RA. Alternative splicing accounts for the four forms of myelin basic protein. Cell 1985, 43:721-727. 10.1016/0092-8674(85)90245-4, 2416470.
29. Hoos MD, Ahmed M, Smith SO, Van Nostrand WE. Myelin basic protein binds to and inhibits the fibrillar assembly of Aβ42 in vitro. Biochemistry 2009, 48:4720-4727. 10.1021/bi900037s, 19385666.
30. Bartzokis G, Lu PH, Geschwind DH, Edwards N, Mintz J, Cummings JL. Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia. Arch Gen Psychiatry 2006, 63:63-72. 10.1001/archpsyc.63.1.63, 16389198.
31. Liu MC, Akle V, Zheng W, Kitlen J, O'Steen B, Larner SF, Dave JR, Tortella FC, Hayes RL, Wang KK. Extensive degradation of myelin basic protein isoforms by calpain following traumatic brain injury. J Neurochem 2006, 98:700-712. 10.1111/j.1471-4159.2006.03882.x, 16893416.
32. Bartzokis G, Lu PH, Geschwind DH, Tingus K, Huang D, Mendez MF, Edwards N, Mintz J. Apolipoprotein E affects both myelin breakdown and cognition: implications for age-related trajectories of decline into dementia. Biol Psychiatry 2007, 62:1380-1387. 10.1016/j.biopsych.2007.03.024, 17659264.
33. Bartzokis G, Sultzer D, Lu PH, Nuechterlein KH, Mintz J, Cummings JL. Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical 'disconnection' in aging and Alzheimer's disease. Neurobiol Aging 2004, 25:843-851. 10.1016/j.neurobiolaging.2003.09.005, 15212838.
34. Marner L, Nyengaard JR, Tang Y, Pakkenberg B. Marked loss of myelinated nerve fibers in the human brain with age. J Comp Neurol 2003, 462:144-152. 10.1002/cne.10714, 12794739.
35. Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, Anthony J, Watson D, Luehrs DC, Sue L, Walker D, Emmerling M, Goux W, Beach T. Increased Aβ peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 2002, 41:11080-11090. 10.1021/bi026173d, 12220172.
36. Mitew S, Kirkcaldie MT, Halliday GM, Shepherd CE, Vickers JC, Dickson TC. Focal demyelination in Alzheimer's disease and transgenic mouse models. Acta Neuropathol 2010, 119:567-577. 10.1007/s00401-010-0657-2, 20198482.
37. Molineaux SM, Engh H, de Ferra F, Hudson L, Lazzarini RA. Recombination within the myelin basic protein gene created the dysmyelinating shiverer mouse mutation. Proc Natl Acad Sci USA 1986, 83:7542-7546. 10.1073/pnas.83.19.7542, 386755, 2429310.
38. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006, 26:10129-10140. 10.1523/JNEUROSCI.1202-06.2006, 17021169.
39. Liu L, Duff K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J Vis Exp 2008, 21:960. 2762909, 19066529.
40. Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, Zlokovic BV, Van Nostrand WE. Early-onset and robust cerebral microvascular accumulation of amyloid β-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid β-protein precursor. J Biol Chem 2004, 279:20296-20306. 10.1074/jbc.M312946200, 14985348.
41. DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, Holtzman DM. Plaque-associated disruption of CSF and plasma amyloid-β (Aβ) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 2002, 81:229-236. 10.1046/j.1471-4159.2002.00889.x, 12064470.
42. Liao MC, Hoos MD, Aucoin D, Ahmed M, Davis J, Smith SO, Van Nostrand WE. N-terminal domain of myelin basic protein inhibits amyloid β-protein fibril assembly. J Biol Chem 2010, 285:35590-35598. 10.1074/jbc.M110.169599, 2975183, 20807757.
43. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43:321-332. 10.1016/j.neuron.2004.07.003, 15294141.
44. Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC. Intraneuronal aβ-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 2001, 125:489-492.
45. Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, Pradier L, Beyreuther K, Bayer TA. Intraneuronal aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett 2001, 306:116-120. 10.1016/S0304-3940(01)01876-6, 11403971.
46. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2007, 2:18. 10.1186/1750-1326-2-18, 2100048, 17897471.
47. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000, 106:1489-1499. 10.1172/JCI10498, 387254, 11120756.
48. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D. Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol 2003, 2:506-511. 10.1016/S1474-4422(03)00487-3, 12878439.
49. Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem 2004, 89:807-811. 10.1111/j.1471-4159.2004.02385.x, 15140180.
50. Privat A, Jacque C, Bourre JM, Dupouey P, Baumann N. Absence of the major dense line in myelin of the mutant mouse 'shiverer'. Neurosci Lett 1979, 12:107-112. 10.1016/0304-3940(79)91489-7, 460693.
51. Nagaike K, Mikoshiba K, Tsukada Y. Dysmyelination of shiverer mutant mice in vivo and in vitro. J Neurochem 1982, 39:1235-1241. 10.1111/j.1471-4159.1982.tb12560.x, 6750046.
52. Gottschall PE, Yu X, Bing B. Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. J Neurosci Res 1995, 42:335-342. 10.1002/jnr.490420307, 8583501.
53. Muir EM, Adcock KH, Morgenstern DA, Clayton R, von Stillfried N, Rhodes K, Ellis C, Fawcett JW, Rogers JH. Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res Mol Brain Res 2002, 100:103-117. 10.1016/S0169-328X(02)00132-8, 12008026.
54. Sbai O, Ould-Yahoui A, Ferhat L, Gueye Y, Bernard A, Charrat E, Mehanna A, Risso JJ, Chauvin JP, Fenouillet E, Rivera S, Khrestchatisky M. Differential vesicular distribution and trafficking of MMP-2, MMP-9, and their inhibitors in astrocytes. Glia 2010, 58:344-366.
55. Beems T, Simons KS, Van Geel WJ, De Reus HP, Vos PE, Verbeek MM. Serum- and CSF-concentrations of brain specific proteins in hydrocephalus. Acta Neurochir (Wien) 2003, 145:37-43. 10.1007/s00701-002-1019-1, 12545260.
56. Abdo WF, van de Warrenburg BP, Munneke M, van Geel WJ, Bloem BR, Kremer HP, Verbeek MM. CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. Neurology 2006, 67:474-479. 10.1212/01.wnl.0000227891.25592.8c, 16894110.
57. Su E, Bell MJ, Kochanek PM, Wisniewski SR, Bayir H, Clark RS, Adelson PD, Tyler-Kabara EC, Janesko-Feldman KL, Berger RP. Increased CSF concentrations of myelin basic protein after TBI in infants and children: absence of significant effect of therapeutic hypothermia. Neurocrit Care 2012, 17:401-407. 10.1007/s12028-012-9767-0, 22890910.
58. Lamers KJ, de Reus HP, Jongen PJ. Myelin basic protein in CSF as indicator of disease activity in multiple sclerosis. Mult Scler 1998, 4:124-126.
59. Landry CF, Ellison JA, Pribyl TM, Campagnoni C, Kampf K, Campagnoni AT. Myelin basic protein gene expression in neurons: developmental and regional changes in protein targeting within neuronal nuclei, cell bodies, and processes. J Neurosci 1996, 16:2452-2462.
60. Landry CF, Pribyl TM, Ellison JA, Givogri MI, Kampf K, Campagnoni CW, Campagnoni AT. Embryonic expression of the myelin basic protein gene: identification of a promoter region that targets transgene expression to pioneer neurons. J Neurosci 1998, 18:7315-7327.
61. Filipovic R, Zecevic N. Interaction between microglia and oligodendrocyte cell progenitors involves Golli proteins. Ann N Y Acad Sci 2005, 1048:166-174. 10.1196/annals.1342.015, 16154930.
62. Harauz G, Ladizhansky V, Boggs JM. Structural polymorphism and multifunctionality of myelin basic protein. Biochemistry 2009, 48:8094-8104. 10.1021/bi901005f, 19642704.
63. Chernoff GF. Shiverer: an autosomal recessive mutant mouse with myelin deficiency. J Hered 1981, 72:128.
64. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, Reiner PB. β-Amyloid efflux mediated by p-glycoprotein. J Neurochem 2001, 76:1121-1128. 10.1046/j.1471-4159.2001.00113.x, 11181832.
65. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV. LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron 2004, 43:333-344. 10.1016/j.neuron.2004.07.017, 15294142.
66. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. Aβ-degrading enzymes in Alzheimer's disease. Brain Pathol 2008, 18:240-252. 10.1111/j.1750-3639.2008.00132.x, 18363935.
67. Nagara H, Suzuki K. Chronological study of oligodendroglial alterations and myelination in quaking mice. Neuropathol Appl Neurobiol 1981, 7:135-149. 10.1111/j.1365-2990.1981.tb00083.x, 7231641.
68. Best TT, Skoff RP, Bartlett WP. Astroglial plasticity in hemizygous and heterozygous jimpy mice. Int J Dev Neurosci 1988, 6:39-57. 10.1016/0736-5748(88)90027-5, 3213569.
69. Dyer CA, Kendler A, Jean-Guillaume D, Awatramani R, Lee A, Mason LM, Kamholz J. GFAP-positive and myelin marker-positive glia in normal and pathologic environments. J Neurosci Res 2000, 60:412-426. 10.1002/(SICI)1097-4547(20000501)60:3<412::AID-JNR16>3.0.CO;2-E, 10797544.
70. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996, 55:300-309. 10.1097/00005072-199603000-00005, 8786388.
71. Liuzzi GM, Latronico T, Fasano A, Carlone G, Riccio P. Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult Scler 2004, 10:290-297. 10.1191/1352458504ms1016oa, 15222694.
72. del Zoppo GJ, Milner R, Mabuchi T, Hung S, Wang X, Berg GI, Koziol JA. Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke 2007, 38:646-651. 10.1161/01.STR.0000254477.34231.cb, 17261708.
73. del Zoppo GJ, Frankowski H, Gu YH, Osada T, Kanazawa M, Milner R, Wang X, Hosomi N, Mabuchi T, Koziol JA. Microglial cell activation is a source of metalloproteinase generation during hemorrhagic transformation. J Cereb Blood Flow Metab 2012, 32:919-932. 10.1038/jcbfm.2012.11, 3345906, 22354151.
74. Roher AE, Kasunic TC, Woods AS, Cotter RJ, Ball MJ, Fridman R. Proteolysis of A β peptide from Alzheimer disease brain by gelatinase A. Biochem Biophys Res Commun 1994, 205:1755-1761. 10.1006/bbrc.1994.2872, 7811262.
75. Backstrom JR, Lim GP, Cullen MJ, Tokes ZA. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-β peptide (1-40). J Neurosci 1996, 16:7910-7919.
76. Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM. Matrix metalloproteinase-9 degrades amyloid-β fibrils in vitro and compact plaques in situ. J Biol Chem 2006, 281:24566-24574. 10.1074/jbc.M602440200, 16787929.
77. Yin KJ, Cirrito JR, Yan P, Hu X, Xiao Q, Pan X, Bateman R, Song H, Hsu FF, Turk J, Xu J, Hsu CY, Mills JC, Holtzman DM, Lee JM. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-β peptide catabolism. J Neurosci 2006, 26:10939-10948. 10.1523/JNEUROSCI.2085-06.2006, 17065436.
78. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, Hill AF, Barnham KJ, Li QX, Bush AI, Masters CL. Degradation of the Alzheimer disease amyloid β-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 2006, 281:17670-17680. 10.1074/jbc.M602487200, 16648635.
79. Kotarba AE, Aucoin DS, Hoos MD, Smith SO, Van Nostrand WE. Fine mapping of the amyloid ss-protein binding site on myelin basic protein. Biochemistry 2013, 52(15):2565-2573. 10.1021/bi4001936, 23510371.